二、监事会会议审议情况 本次会议审议通过了以下议案： 证券代码：300318 证券简称：博晖创新 公告编号：临 2024-034 北京博晖创新生物技术集团股份有限公司 第八届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第七次会议于 2024 年 10 月 29 日在公司会议室召开，会议通知于 2024 年 10 月 18 日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由公司 监事会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本次会议 应出席监事 3 人，实际出席监事 3 人。本次会议的召集召开程序符合《公司法》和 《公司章程》的有关规定。 1、审议通过《2024 年第三季度报告》 监事会认为：公司结合 2024 年第三季度的实际经营管理情况编制的《2024 年 第三季度报告》符合《深圳证券交易所创业板股票上市规则》、《上市公司信息披露 管理办法》等法律、法规的相关要求。其内容真实、准确、完整的反映了公 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2024-033 本次会议审议通过了以下议案： 1、审议通过《2024 年第三季度报告》 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第八次会议于 2024 年 10 月 29 日在公司会议室召开，会议通知于 2024 年 10 月 18 日以专人送达、邮件通知或电话通知的方式送达各位董事，会 议由公司董事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行，本 次会议应出席董事 7 人，实际出席董事 7 人，监事列席了会议。本次会议的召集 召开程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 北京博晖创新生物技术集团股份有限公司 第八届董事会第八次会议决议公告 同意公司根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所 创业板上市公司第 47 号——上市公司季度报告公告格式》等法律、法规的相关 要求，结合本公司 2024 年第三季度的实际经营管理情况编制《202 ...

Financial Performance - The company's revenue for Q3 2024 was ¥159,179,087.52, a decrease of 42.99% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥3,916,037.20, representing a decline of 147.69% year-over-year[3]. - The basic earnings per share (EPS) was -¥0.0048, down 147.52% from the previous year[3]. - Total operating revenue for Q3 2024 was ¥646,068,014.18, a decrease of 19.9% compared to ¥806,104,920.39 in Q3 2023[21]. - Net profit for Q3 2024 reached ¥45,007,016.93, compared to ¥14,422,884.59 in Q3 2023, representing a significant increase[22]. - The total comprehensive income attributable to the parent company for Q3 2024 is CNY 23,763,225.14, an increase from CNY 15,366,696.38 in the same period last year, representing a growth of approximately 54.5%[23]. - Basic and diluted earnings per share for Q3 2024 are both CNY 0.0290, up from CNY 0.0173 in the same period last year, reflecting an increase of approximately 67.7%[23]. Assets and Liabilities - Total assets increased to ¥4,115,135,732.47, reflecting a growth of 4.82% compared to the end of the previous year[3]. - The company's total assets increased to ¥4,115,135,732.47, up from ¥3,926,015,273.52 year-over-year[21]. - Non-current liabilities rose to ¥726,258,030.90, compared to ¥520,619,946.13 in the previous year, indicating a 39.4% increase[20]. - The total liabilities increased to ¥1,729,539,735.82, compared to ¥1,585,470,244.35 in the previous year, marking a 9.1% rise[20]. - Long-term borrowings rose by 61.29% to ¥549,880,314.57, attributed to increased bank loans by subsidiaries[7]. - The company's total equity attributable to shareholders increased by 1.74% to ¥1,393,301,767.52 compared to the end of the previous year[3]. - The total equity attributable to shareholders of the parent company was ¥1,393,301,767.52, an increase from ¥1,369,538,542.38 in the previous year[20]. Cash Flow - The cash flow from operating activities for the first nine months of 2024 was -¥12,088,916.80, a significant decrease of 111.67% year-over-year[10]. - The net cash flow from operating activities for Q3 2024 is CNY -12,088,916.80, a significant decrease compared to CNY 103,617,734.96 in Q3 2023[25]. - The total cash inflow from financing activities for Q3 2024 is CNY 1,048,461,585.92, down from CNY 1,428,966,671.91 in the previous year, indicating a decline of about 26.6%[26]. - The cash flow from investment activities for Q3 2024 is CNY -150,866,059.82, slightly worse than CNY -150,795,903.23 in the previous year[25]. - The total cash outflow from operating activities in Q3 2024 is CNY 730,052,111.70, compared to CNY 774,303,723.06 in Q3 2023, showing a decrease of about 5.7%[25]. - The cash and cash equivalents at the end of Q3 2024 amount to CNY 97,274,347.95, an increase from CNY 63,634,797.87 at the end of Q3 2023[26]. - The company's cash and cash equivalents increased to ¥118,363,873.12 from ¥104,925,738.92 at the beginning of the period, representing a growth of approximately 12.9%[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,750[11]. - The largest shareholder, Du Jiangtao, holds 39.03% of the shares, totaling 318,811,388 shares[12]. - The total number of shareholders with more than 5% ownership includes several individuals, with Du Jiangtao and Hao Hong being the most significant[12]. Operational Developments - The company obtained single plasma collection licenses for two subsidiaries, enhancing its operational capabilities[15]. - The respiratory pathogen six-fold nucleic acid detection kit received regulatory approval, expanding the product portfolio[15]. - The company signed a guarantee contract with China Construction Bank for a maximum of ¥326,582,300 to support its subsidiary[17]. - The company terminated a project cooperation contract related to rabies vaccine clinical trials, indicating a strategic shift in R&D focus[16]. Income and Expenses - The company's operating costs for the first nine months of 2024 were ¥318,826,772.88, down 31.05% from ¥462,435,519.21 in the same period last year[8]. - Total operating costs for Q3 2024 were ¥602,017,288.79, down 22.0% from ¥772,229,494.76 in the same period last year[21]. - Research and development expenses for Q3 2024 were ¥43,286,170.11, down from ¥53,646,814.14 in Q3 2023, reflecting a 19.4% decrease[21]. - Other income increased by 33.99% to ¥6,325,797.51, primarily due to government subsidies[8]. - The company reported a significant increase in non-operating income of 632.74%, totaling ¥18,276,629.93, mainly from compensation received for terminated clinical trials[9]. - Accounts receivable decreased to ¥41,083,685.84 from ¥53,895,164.57, indicating a decline of about 23.7%[18]. - Inventory increased significantly to ¥982,671,789.28 from ¥854,562,676.21, reflecting a rise of approximately 15%[18]. - The company reported a decrease in cash received from sales of goods and services, totaling CNY 672,247,502.42 in Q3 2024, down from CNY 838,698,516.96 in Q3 2023, a decline of approximately 19.8%[24].

近日，公司与中国建设银行股份有限公司石家庄开发区支行（以下简称"建 设银行"）签订《本金最高额保证合同》（合同编号：HTC130612000ZGDB2024N009） 和《主债权及不动产最高额抵押合同》（合同编号：BHSW-DYHT-202402），同 意为河北博晖在建设银行于2024年9月18日至2027年12月31日期间签订的"人民 币资金借款合同、外汇资金借款合同、银行承兑协议、信用证开证合同、出具保 函协议及/或其他法律性文件（以下简称"主合同"）"提供连带责任保证担保， 担保的最高债权额（《本金最高额保证合同》与《主债权及不动产最高额抵押合 1 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 北京博晖创新生物技术集团股份有限公司（以下简称"公司"）分别于2024年 4月25日、2024年5月17日召开第八届董事会第五次会议、第八届监事会第四次会 议、2023年度股东大会，审议通过了《关于2024年度担保额度预计的议案》，同 意公司为控股子公司博晖生物制药（河北）有限公司（以下简称"河北博晖"）、 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2024-031 北京博晖创新生物技术集团股份有限公司 关于控股孙公司终止项目合作合同及药物临床试验的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"）控股孙公司博 晖生物制药股份有限公司（曾用名：中科生物制药股份有限公司，以下简称"廊 坊博晖"）与成都柏奥特克生物科技股份有限公司（以下简称"柏奥特克"）于 2020 年 1 月签订《项目合作合同》，就柏奥特克完成了临床前研究工作的冻干人用狂 犬病疫苗（无血清 Vero 细胞）进行联合申报。2020 年 7 月该疫苗获得国家药品 监督管理局核准签发的《药物临床试验批准通知书》。2024 年 9 月廊坊博晖与 柏奥特克及其他相关方签订《<项目合作合同>之补充协议》，约定满足条件后， 终止双方于 2020 年 1 月签订的《项目合作合同》，并终止双方合作研发的冻干人 用狂犬病疫苗（无血清 Vero 细胞）的临床试验。近日，廊坊博晖收到柏奥特克 支付的全部补偿款项，《项目合作合同》正式终止。具体情况如 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2024-030 北京博晖创新生物技术集团股份有限公司 关于控股子公司下属浆站取得单采血浆许可证的公告 近日，北京博晖创新生物技术集团股份有限公司（以下简称"公司"）控股子 公司博晖生物制药（河北）有限公司下属大关博晖单采血浆有限公司（以下简称 "大关浆站"）取得云南省卫生健康委员会颁发的《单采血浆许可证》，大关浆站 经核准登记，准予执业。主要信息如下： 一、大关浆站主要信息 机构名称：大关博晖单采血浆站； 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 法定代表人：崔卫东； 主要负责人：李瑞波； 地址：云南省昭通市大关县翠华镇上石厂顺城路 53 号； 业务项目：原料血浆采集； 许可证号：云卫浆准字[2024]第 04 号； 采浆区域：大关县行政区域内（玉碗镇、木杆镇、悦乐镇、高桥镇、寿山镇 除外）； 生产单位：博晖生物制药（河北）有限公司； 2024 年 9 月 12 日 有效期限：2024 年 9 月 11 日至 2026 年 9 月 10 日。 特此公告。 北京博晖创新生物技术集团股份有限公司 董 ...

4、注册证有效期：2024 年 9 月 10 日至 2029 年 9 月 9 日 证券代码：300318 证券简称：博晖创新 公告编号：临 2024-029 北京博晖创新生物技术集团股份有限公司 关于公司获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 近日获得由国家药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外 诊断试剂）》。具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：呼吸道病原体六重核酸检测试剂盒（PCR-荧光探针法） 2、注册分类：Ⅲ类 3、注册证编号：国械注准 20243401723 特此公告。 北京博晖创新生物技术集团股份有限公司 董 事 会 2024 年 9 月 11 日 5、预期用途：本产品用于定性检测人咽拭子样本中的呼吸道病原体，包括 甲型流感病毒（季节性 H1N1、新型甲型 H1N1 流感病毒（2009）、H3N2、H5N1、 H7N9）、乙型流感病毒（Victoria 系和 Yamagata 系）、腺病毒（B 组、C 组 ...

证券代码： 300318 证券简称：博晖创新 北京博晖创新生物技术集团股份有限公司 投资者关系活动记录表 编号：2024-07 特定对象调研 □分析师会议 投资者关系 □媒体采访 □业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名 称及人员姓 详见附件 名 | --- | --- | --- | |------------|-------------------------------------------|--------------------------------------------------------------------| | | | | | 时间 | 2024 年 9 月 3 日 16:00-17:00 | | | 地点 | 公司会议室 | | | 上市公司接 | | | | 待人员姓名 | 董事、副总经理、董事会秘书 | 董海锋先生 | | | | | | | 1 | 、静丙、白蛋白目前的供需关系及价格情况？ | | | | 答：白蛋白目前整体供应相对稳定，因 6-9 月为白蛋白消耗淡 | | | | 季等因素，终端需求略微下 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2024, representing a 15% increase compared to the same period last year[7]. - The company has projected a revenue growth of 10% for the second half of 2024, aiming for a total annual revenue of RMB 1.1 billion[7]. - The company's operating revenue for the reporting period was ¥486.89 million, a decrease of 7.60% compared to the same period last year[12]. - Net profit attributable to shareholders was ¥27.63 million, representing a significant increase of 366.35% year-over-year[12]. - The net profit after deducting non-recurring gains and losses was ¥26.34 million, up 404.11% from the previous year[12]. - The total comprehensive income for the first half of 2024 was CNY 56,026,235.20, compared to CNY 4,545,475.32 in the same period of 2023, marking a substantial improvement[164]. - The company reported a significant increase in investment income, with a total of CNY 927,618.84 in the previous year, indicating a positive trend in investment performance[165]. - The company reported a total comprehensive income increase of approximately 86.5% year-over-year[182]. User Growth and Market Expansion - User data indicates a growth in active users by 20%, reaching a total of 1.2 million users as of June 30, 2024[7]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in sales in that region by the end of 2024[7]. - The company aims to enhance its market presence through the introduction of advanced diagnostic technologies and products[21]. Product Development and Innovation - New product development includes the launch of a microfluidic chip technology, expected to enhance diagnostic capabilities and increase market share[7]. - The company has invested RMB 50 million in R&D for new diagnostic technologies, focusing on molecular diagnostics and HPV detection[7]. - The company continues to develop new products, including a Nucleic Acid Chip Detector for HPV testing, with a registration validity until November 2028[21]. - The company is focused on expanding its product offerings in the field of medical diagnostics, particularly in the detection of trace elements and viral infections[21]. - The company has developed a human trace element detection platform based on atomic absorption and a molecular diagnostic platform based on microfluidic control technology[52]. Financial Management and Investments - The company maintains a strong cash position with RMB 300 million in cash reserves, providing flexibility for future investments[7]. - No cash dividends will be distributed for the current fiscal year, as the company aims to reinvest profits into growth initiatives[2]. - The company has received multiple new patents, including a method for nucleic acid extraction and a hydrogenation reaction device, indicating ongoing innovation[38]. - The company has reported a total investment of CNY 72,342.68 for hazardous waste disposal in Hebei[102]. Regulatory and Compliance - The management has identified potential risks related to regulatory changes and market competition, with strategies in place to mitigate these risks[2]. - The company is committed to adhering to regulatory requirements for innovative medical devices, as indicated by the registration status of its products[20]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, adhering to various environmental standards[63]. Environmental Management - The company has implemented various environmental protection laws and standards in its operations, including the Environmental Protection Law and the Air Pollution Prevention and Control Law[66]. - The company has established a comprehensive quality management system to ensure product safety, complying with national drug production and quality management standards[54]. - The company is committed to maintaining compliance with environmental standards and reducing pollutant emissions[71]. Shareholder and Corporate Governance - The total number of shares outstanding is 816,900,495, with 97.75% being unrestricted shares[144]. - The company has not issued any new shares or conducted any share buybacks during the reporting period[144]. - The company has not reported any changes in the number of restricted shares during the reporting period[144]. - The company has made commitments to avoid conflicts of interest and ensure independent operations, with no violations reported during the reporting period[108]. Risks and Challenges - The company faces risks in medical device product development due to external uncertainties and the complexity of innovation projects[52]. - The company is facing potential risks related to the management of blood plasma collection stations, despite having established a set of management protocols[55]. - The company is currently working on the resumption of production at the Langfang facility, which requires government approval, posing a risk of delays[56]. Future Outlook - Future outlook includes continued innovation in medical technology and expansion of product lines to meet market demands[21]. - The company plans to continue focusing on market expansion and new product development to drive future growth[163].

北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第七次会议于 2024 年 8 月 29 日在公司会议室召开，会议通知于 2024 年 8 月 19 日以专人送达、邮件通知或电话通知的方式送达各位董事，会议 由公司董事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行，本次 会议应出席董事 7 人，实际出席董事 7 人，监事和高级管理人员列席了会议。本 次会议的召集召开程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 证券代码：300318 证券简称：博晖创新 公告编号：临 2024-027 北京博晖创新生物技术集团股份有限公司 第八届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 本次会议审议通过了以下议案： 1、审议通过《2024 年半年度报告及其摘要》 同意公司根据《深圳证券交易所创业板股票上市规则》、《公开发行证券的公 司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》等法律、法规 的相关要求，结合本公司 2024 年上半年的实际经 ...